Pfizer is a leading research-based biopharmaceutical company, and has made an equity investment in Cellectis. Together, we are collaborating globally on 15 targets, including the first allogeneic BCMA CAR-T, which can have powerful activity against cancers like measurable multiple myeloma.
Servier is the leading French independent pharmaceutical company. Cellectis and Servier are collaborating on five targets, including UCART19, with ongoing pediatric and adult trials sponsored by Servier in the UK.
"Collaborating closely with Cellectis on UCART19, an innovative cellular therapy candidate against lymphoid malignancies, Servier’s team constantly explores new horizons and delivers the utmost best of their expertise. Together, our highly complementary competencies and know-how give our teams the best chances of providing patients worldwide with a new generation of cancer treatments they need."
Olivier Laureau, President of Servier